The synthesis and the antimicrobial activity of N1-substituted 5-amino-4-arylsulfonyl-3-N-phenylaminopyrazoles
DOI:
https://doi.org/10.24959/nphj.17.2159Keywords:
5-aminopyrazole, synthesis, antimicrobial activity, antifungal activityAbstract
This article is continuation of the development of methods for the synthesis of small molecules based on the structure of 5-aminopyrazole. The synthesis and the antimicrobial activity for a series of new N1-subsituted 5-amino-4-arylsulfonyl-3-N-phenylaminopyrazoles have been described.
Aim. To synthesize derivatives of 5-amino-4-arylsulfonyl-3phenylaminopyrazoles and study their antimicrobial and antifungal properties.
Materials and methods. The methods of organic synthesis, instrumental methods of organic compounds analysis and methods of microbiological screening were used.
Results and discussion. 5-Amino-4-arylsulfonyl-3-phenylaminopyrazoles were prepared by the reaction of arylsulfonylacetonitriles with isothiocyanates in the presence of NaOH and CH3I with further cyclization with hydrazine hydrate. The reaction of this compounds with N-arylchloroacetamides finished a series of N1-substituted 5-amino-4-arylsulfonyl-3-phenylaminopyrazoles. The antibacterial and antifungal properties of the compounds synthesized were studied. Some of the compounds obtained appeared to be potent inhibitors for several pathogenic bacterial and fungal lines.
Conclusions. The synthetic scheme for obtaining of N1-substituted 5-amino-4-arylsulfonyl-3-phenylaminopyrazoles, which can be used for creation of a library of compounds for in vitro antimicrobial screening, has been proposed. Some of the compounds synthesized are of certain interest as potential pharmaceutical agents and can be used to develop new antifungal agents.
References
Hughes, D. L. (2017). Patent Review of Manufacturing Routes to Fifth–Generation Cephalosporin Drugs. Part 1, Ceftolozane. Organic
Process Research & Development, 21 (3), 430–443. doi: 10.1021/acs.oprd.7b00033
Lawrence, H. R., Martin, M. P., Luo, Y., Pireddu, R., Yang, H., Gevariya, H., Ozcan, S., Zhu, J.–Y., Kendig, R., Rodriguez, M., Elias,
R., Cheng, J. Q., Sebti, S. M., Schonbrunn, E., Lawrence, N. J. (2012). Development of o–Chlorophenyl Substituted Pyrimidines as
Exceptionally Potent Aurora Kinase Inhibitors. Journal of Medicinal Chemistry, 55 (17), 7392–7416. doi: 10.1021/jm300334d
Bekhit, A. A., Ashour, H. M., Abdel Ghany, Y. S., Bekhit, Ael–D., Baraka, A. (2008). Synthesis and biological evaluation of some thiazolyl
and thiadiazolyl derivatives of 1H–pyrazole as anti–inflammatory antimicrobial agents. European Journal of Medicinal Chemistry,
(3), 456–463. doi: 10.1016/j.ejmech.2007.03.030
Weston, C. E., Krämer, A., Colin, F., Yildiz, Ö., Baud, M. G. J., Meyer–Almes, F., Fuchter, M. J. (2017). Toward Photopharmacological
Antimicrobial Chemotherapy Using Photoswitchable Amidohydrolase Inhibitors. ACS Infectious Diseases, 3(2), 152–161.
doi: 10.1021/acsinfecdis.6b00148
Tkachenko, P. V., Tkachenko, E. V., Zhuravel, I. A., Kazmirchuk, V. V., Derbisbekova, U. B. (2017). Vestnik KazNMU, 2, 307–311.
Tkachenko, P. V., Tkachenko, O. V., Netosova, K. Y., Borisov, O. V., Zhuravel, I. O. (2017). The synthesis of the substituted 4–alkyl/
arylsulfonyl–5–amino–3–alkylthiopyrazoles as promising pharmaceutical agents with the antifungal action. Vìsnik Farmacìï, 2(90),
–30. doi: 10.24959/nphj.17.2158
Bruno, O., Brullo, C., Bondavalli, F., Schenone, S., Ranise, A., Arduino, N., Bertolotto, M. B., Montecucco, F., Ottonello, L., Dallegri,
F., Tognolini, M., Ballabeni, V., Bertoni, S., Barocelli, E. (2007). Synthesis and Biological Evaluation of N–Pyrazolyl–N‘–alkyl/benzyl/
phenylureas: a New Class of Potent Inhibitors of Interleukin 8–Induced Neutrophil Chemotaxis. Journal of Medicinal Chemistry,
(15), 3618–3626. doi: 10.1021/jm0704402
Celoni, M., Godoya, M., Fighera, M. R., Souza, F. R., Flores, A. E., Rubin, M. A., Oliveira, M. R., Zanatta, N., Martins, M. A., Bonacorso,
H. G., Mello, C. F. (2004). α2–Adrenoceptors and 5–HT receptors mediate the antinociceptive effect of new pyrazolines, but not
of dipyrone. European Journal of Pharmacology, 496 (1–3), 93–97. doi: 10.1016/j.ejphar.2004.05.045
Smurnyy, Y., Toms, A. V., Hickson, G. R., Eck, M. J., Eggert, U. S. (2010). Binucleine 2, an isoform–specific inhibitor of Drosophila Aurora
B kinase, provides insights into the mechanism of cytokinesis. ACS Chemical Biology, 5 (11), 1015–1020. doi: 10.1021/cb1001685
Vizirianakis, I. S., Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., Tsiftsoglou, A. S. (2010). Toward the Development
of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and
Perspectives. Journal of Medicinal Chemistry, 53 (19), 6779–6810. doi: 10.1021/jm100189a
Swain, N., Batchelor, D., Beaudoin, S., Bechle, B., Bradley, P. (2017). Discovery of Clinical Candidate 4–[2–(5–Amino–1H–pyrazol–
–yl)–4–chlorophenoxy]–5–chloro–2–fluoro–N–1,3–thiazol–4–ylbenzenesulfonamide (PF–05089771): Design and Optimization
of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7. Journal of Medical Chemistry, 60 (16), 7029–7042. doi: 10.1021/
acs.jmedchem.7b00598
Planken, S., Behenna, D., Nair, S., Johnson, T., Nagata, A. (2017). Discovery of N–((3R,4R)–4–Fluoro–1–(6–((3–methoxy–1–methyl–
H–pyrazol–4–yl)amino)–9–methyl–9H–purin–2–yl)pyrrolidine–3–yl)acrylamide (PF–06747775) through Structure–Based Drug Design:
A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild–Type EGFR. Journal of
Medical Chemistry, 60 (7), 3002–3019. doi: 10.1021/acs.jmedchem.6b01894
Crawford, T. D., Romero, F. A., Lai, K.W., Tsui, V., Taylor, A. M. (2016). Discovery of a Potent and Selective in Vivo Probe (GNE–272)
for the Bromodomains of CBP/EP300. Journal of Medical Chemistry, 59 (23), 10549–10563. doi: 10.1021/acs.jmedchem.6b01022
Zhang, Ch.–H., Chen, K., Jiao, Y., Li, L., Li, Ya., Zhang, R., Zheng, M., Zhong, L., Huang, Sh., Song, Ch., Lin, W., Yang, J., Xiang,
R., Peng, B., Han, J., Lu, G., Wei, Y., Yang, Sh. (2016). From Lead to Drug Candidate: Optimization of 3–(Phenylethynyl)–1H–
pyrazolo[3,4–d]pyrimidin–4–amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. Journal of Medical
Chemistry, 59 (21), 9788–9805. doi: 10.1021/acs.jmedchem.6b00943
Ai, T., Willett, R., Williams, J., Ding, R., Wilson, D. J., Xie, J., Kim, D. H., Puertollano, R., Chen, L. (2017). N–(1–Benzyl–3,5–dimethyl–
H–pyrazol–4–yl)benzamides: Antiproliferative Activity and Effects on mTORC1 and Autophagy. ACS Medicinal Chemistry
Letters, 8 (1), 90–95. doi: 10.1021/acsmedchemlett.6b00392
Kaufmann, K., Romaine, I., Days, E., Pascual, C., Malik, A., Yang, L., Zou, B., Du, Y., Sliwoski, G., Morrison, R. D., Denton, J., Niswender,
C. M., Daniels, J. S., Sulikowski, G. A., Xie, X. S., Lindsley, C. W., Weaver, C. D. (2013). ML297 (VU0456810), the first potent and
selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chemical Neuroscience, 4 (19),
–1286. doi: 10.1021/cn400062a
Wen, W., Wu, W., Romaine, I. M., Kaufmann, K., Du, Y., Sulikowski, G. A., Weaver, C. D., Lindsley, C. W. (2013). Discovery of
‘molecular switches’ within a GIRK activator scaffold that afford selective GIRK inhibitors. ACS Chemical Neuroscience, 23 (16),
–4566. doi: 10.1016/j.bmcl.2013.06.023
Wieting, J. M., Vadukoot, A. K., Sharma, S., Abney, K. K., Bridges, T. M., Daniels, J. S., Morrison, R. D., Wickman, K., Weaver,
C. D., Hopkins, C. R. (2017). Discovery and Characterization of 1H–Pyrazol–5–yl–2–phenylacetamides as Novel, Non–Urea–Containing
GIRK1/2 Potassium Channel Activators. ACS Chemical Neuroscience. doi: 10.1021/acschemneuro.7b00217
Dömling, A. (2006). Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry. Chemical Reviews,
(1), 17–89. doi: 10.1021/cr0505728
Shao, N., Chen, T., Zhang, T., Zhu, H., Zheng, Q., Zou, H. (2014). Cascade regioselective synthesis of pyrazoles from nitroallylic acetates
and N–tosyl hydrazine. Tetrahedron, 70 (4), 795–799. doi: 10.1016/j.tet.2013.12.046
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
